Effect of magnetic stimulation in the management of chronic migraine

To determine the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in the management of chronic migraine: A randomized sham control, open level study

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037215

Enrollment

Registered

2021-10-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G437- Chronic migraine without aura

Interventions

Intervention1: Repetitive transcranial magnetic stimulation: The chronic migraine patients, repetitive transcranial magnetic stimulation impulses were given in 10 trains, each consisting of 60 pulses

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patient fulfilling the diagnostic criteria of chronic migraine that is â??headaches on 15 or more days per month in a patient with prior migraine history, with at least 8 days per month being migraine for at least 3 months 2) Adults >18 years of age with above mentioned criteria

Exclusion criteria

Exclusion criteria: Patients with pregnancy, CLD or CKD, malignancy, severe hypertension, pacemaker or metallic implants, and history of seizure or structural brain lesions, Type 2 DM, Heart Failure, Peripheral neuropathy have been excluded

Design outcomes

Primary

Measure	Time frame
The primary outcome measures were defined at 1 month as follows: (a)Reduction in headache frequency by 50% (b)Improvement in severity on Visual Analogue Scale (VAS) (0-100) by 50% c)Functional disability d)Rescue medication Timepoint: The primary outcome measures were defined at 1 month as follows: (a)Reduction in headache frequency by 50% (b)Improvement in severity on Visual Analogue Scale (VAS) (0-100) by 50% c)Functional disability d)Rescue medication	—

Measure

Time frame

The primary outcome measures were defined at 1 month as follows: (a)Reduction in headache frequency by 50% (b)Improvement in severity on Visual Analogue Scale (VAS) (0-100) by 50% c)Functional disability d)Rescue medication Timepoint: The primary outcome measures were defined at 1 month as follows: (a)Reduction in headache frequency by 50% (b)Improvement in severity on Visual Analogue Scale (VAS) (0-100) by 50% c)Functional disability d)Rescue medication

—

Secondary

Measure	Time frame
Secondary outcome will be a) BP change after 3 min standing b) Heart rate change after 3 min standing c) BP response to isometric hand grip d)Postural dizziness, palpitation, peripheral flushing, sweating, dry eye and dry mouth Timepoint: 1 month	—

Countries

India

Contacts

Public ContactAbinash swain

AIIMS Bhubaneswar

sanjeev_bhoi@rediffmail.com7008454917

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026